Symptoms related to the menstrual cycle: Diagnosis, prevalence, and treatment

Journal of Psychiatric Practice

Volumn 14, Issue 1, 2008, Pages 13-21

  Clayton, Anita H ^a,b  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Dysmenorrhea; Menstrual cycle related symptoms; Menstruation; Nonsteroidal anti inflammatory drugs; Oral contraceptives; Ovulation suppression; Premenstrual dysphoric disorder; Premenstrual symptoms; Selective serotonin reuptake inhibitors

Indexed keywords

ACETYLSALICYLIC ACID; ANXIOLYTIC AGENT; ESTROGEN; FLUOXETINE; GONADORELIN AGONIST; IBUPROFEN; LEUPRORELIN; MEFENAMIC ACID; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PAROXETINE; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; PROGESTERONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ANXIETY; APPETITE DISORDER; ARTICLE; BEHAVIOR DISORDER; BLOATING; BREAST TENDERNESS; CLINICAL TRIAL; DEPRESSION; DIET THERAPY; DISEASE ASSOCIATION; DRUG EFFICACY; DYSMENORRHEA; EMOTIONAL DISORDER; EXERCISE; FATIGUE; HEADACHE; HEALTH SURVEY; HEART DISEASE; HEREDITY; HOT FLUSH; HUMAN; IRRITABILITY; LEISURE; LUTEAL PHASE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; OVULATION INHIBITION; PREMENSTRUAL DYSPHORIC DISORDER; PREMENSTRUAL SYNDROME; PSYCHOSOCIAL WITHDRAWAL; QUALITY OF LIFE; SIDE EFFECT; SLEEP DISORDER; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DIETARY SUPPLEMENTS; DRUG THERAPY; FEMALE; HUMANS; LIFE STYLE; MENSTRUAL CYCLE; MIDDLE AGED; OVULATION INHIBITION; PREMENSTRUAL SYNDROME; PREVALENCE; SEROTONIN UPTAKE INHIBITORS;

EID: 38549095505     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.pra.0000308491.54885.f8     Document Type: Article

References (80)

1. Rebar RW, Erickson GF. Menstrual cycle and fertility. In: Goldman L, Ausiello D, eds. Cecil textbook of medicine. Philadelphia: W.B. Saunders; 2004:1495-504.
2. Couchman GM, Hammond CB. Physiology of reproduction. In: Scott JR, Di Saia PJ, Hammond CB, et al. eds. Danforth's obstetrics and gynecology. Philadelphia: Lippincott Williams & Wilkins; 1999:47-63.
3. Guyton A, Hall J. Female physiology before pregnancy and the female hormones. In: Guyton A, Hall J, eds. Textbook of medical physiology. Philadelphia: W.B. Saunders; 1996:1017-32.
4. American College of Obstetricians and Gynecologists. ACOG Committee on Practice Bulletins-Gynecology. Premenstrual syndrome: Clinical management guidelines for obstetriciangynecologists. ACOG Pract Bull 2000;15:448-55.
5. Yonkers KA. Management strategies for PMS/PMDD. J Fam Pract 2004;suppl:S15-S20.
6. Dawood MY. Dysmenorrhea. Clin Obstet Gynecol 1990;33:168-78.
7. National Institute of Mental Health. Premenstrual syndrome. 2007 (available at www.4women.gov/FAQ/pms.htm, accessed October 15, 2007).
8. World Health Organization. International classification of diseases, tenth revision. 2003 (available at www.who.int/classifications/icd/en, accessed 11/27/07).
9. Connolly M. Premenstrual syndrome: An update on definitions, diagnosis and management. Adv Psychiatr Treat 2001;7:469-77.
10. Freeman EW. Premenstrual syndrome and premenstrual dysphoric disorder: Definitions and diagnosis. Psychoneuroendocrinology 2003;28(suppl 3):25-37.
11. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. Psychiatry Res 1996;65:97-106.
12. American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th edition, text revision. Washington, DC: American Psychiatric Association; 2000.
13. Borenstein J, Chiou CF, Dean B, et al. Estimating direct and indirect costs of premenstrual syndrome. J Occup Environ Med 2005;47:26-33.
14. Dean BB, Borenstein JE. A prospective assessment investigating the relationship between work productivity and impairment with premenstrual syndrome. J Occup Environ Med 2004;46:649-56.
15. Halbreich U, Borenstein J, Pearlstein T, et al. The prevalence, impairment, impact, and burden of premenstrual dysphoric disorder (PMS/PMDD). Psychoneuroendocrinology 2003;28 (suppl 3):1-23.
16. Kjerulff KH, Erickson BA, Langenberg PW. Chronic gynecological conditions reported by US women: Findings from the National Health Interview Survey, 1984 to 1992. Am J Public Health 1996;86:195-9.
17. Kjerulff KH, Frick KD, Rhoades JA, et al. The cost of being a woman: A national study of health care utilization and expen-ditures for female-specific conditions. Womens Health Issues 2007;17:13-21.
18. Wittchen HU, Becker E, Lieb R, et al. Prevalence, incidence and stability of premenstrual dysphoric disorder in the community. Psychol Med 2002;32:119-32.
19. Curtis KM, Hillis SD, Kieke BA, Jr., et al. Visits to emergency departments for gynecologic disorders in the United States, 1992-1994. Obstet Gynecol 1998;91:1007-12.
20. Borenstein JE, Dean BB, Endicott J, et al. Health and economic impact of the premenstrual syndrome. J Reprod Med 2003;48:515-24.
21. Hylan TR, Sundell G, Judge R. The impact of premenstrual symptomatology on functioning and treatment-seeking behavior: Experience from the United States, United Kingdom and France. J Womens Health Gend Based Med 1999;8:1043-52.
22. Strine TW, Chapman DP, Ahluwalia IB. Menstrual-related problems and psychological distress among women in the United States. J Womens Health (Larchmt) 2005;14:316-23.
23. Kessler RC, Andrews G, Colpe LJ, et al. Short screening scales to monitor population prevalences and trends in non-specific psychological distress. Psychol Med 2002;32:959-76.
24. Backstrom T, Andreen L, Birzniece V, et al. The role of hormones and hormonal treatments in premenstrual syndrome. CNS Drugs 2003;17:325-42.
25. Schmidt PJ, Nieman LK, Danaceau MA, et al. Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome. N Engl J Med 1998;338:209-16.
26. Parry BL, Rausch JL. Premenstrual dysphoric disorder. In: Kaplan HI, Sadock BJ, Cancro R, eds. Comprehensive textbook of psychiatry. Baltimore: Williams & Wilkins; 1995:1707-13.
27. Mitwally MF, Kahn LS, Halbreich U. Pharmacotherapy of premenstrual syndromes and premenstrual dysphoric disorder: Current practices. Expert Opin Pharmacother 2002;3:1577-90.
28. Coccaro EF. Central serotonin and impulsive aggression. Br J Psychiatry Suppl 1989;52-62.
29. Jovanovic H, Cerin A, Karlsson P, et al. A PET study of 5-HT1A receptors at different phases of the menstrual cycle in women with premenstrual dysphoria. Psychiatry Res 2006;148:185-93.
30. Inoue Y, Terao T, Iwata N, et al. Fluctuating serotonergic function in premenstrual dysphoric disorder and premenstrual syndrome: Findings from neuroendocrine challenge tests. Psychopharmacology (Berl) 2007;190:213-9.
31. Clayton AH, Keller AE, Leslie C, et al. Exploratory study of premenstrual symptoms and serotonin variability. Arch Womens Ment Health 2006;9:51-7.
32. Cone RI, Davis GA, Goy RW. Effects of ovarian steroids on serotonin metabolism within grossly dissected and microdissected brain regions of the ovariectomized rat. Brain Res Bull 1981;7:639-44.
33. Mishell DR, Jr. Contraception. N Engl J Med 1989;320:777-87.
34. Redei E, Freeman EW. Daily plasma estradiol and progesterone levels over the menstrual cycle and their relation to premenstrual symptoms. Psychoneuroendocrinology 1995;20:259-67.
35. Rose DP, Adams PW. Oral contraceptives and tryptophan metabolism: Effects of oestrogen in low dose combined with a progestogen and of a low-dose progestogen (megestrol acetate) given alone. J Clin Pathol 1972;25:252-8.
36. Freeman EW, Rickels K, Sondheimer SJ, et al. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: A randomized controlled trial. Arch Gen Psychiatry 1999;56:932-9.
37. French L. Dysmenorrhea. Am Fam Physician 2005;71:285-91.
38. Zhang WY, Li Wan PA. Efficacy of minor analgesics in primary dysmenorrhoea: A systematic review. Br J Obstet Gynaecol 1998;105:780-9.
39. Steiner M. Premenstrual syndrome and premenstrual dysphoric disorder: Guidelines for management. J Psychiatry Neurosci 2000;25:459-68.
40. Wurtman JJ, Brzezinski A, Wurtman RJ, et al. Effect of nutrient intake on premenstrual depression. Am J Obstet Gynecol 1989;161:1228-34.
41. Thys-Jacobs S, Starkey P, Bernstein D, et al. Calcium carbonate and the premenstrual syndrome: Effects on premenstrual and menstrual symptoms. Premenstrual Syndrome Study Group. Am J Obstet Gynecol 1998;179:444-52.
42. Facchinetti F, Borella P, Sances G, et al. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol 1991;78:177-81.
43. Bhatia SC, Bhatia SK. Diagnosis and treatment of premenstrual dysphoric disorder. Am Fam Physician 2002;66:1239-48.
44. Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: Systematic review. BMJ 1999;318:1375-81.
45. London RS, Murphy L, Kitlowski KE, et al. Efficacy of alphatocopherol in the treatment of the premenstrual syndrome. J Reprod Med 1987;32:400-4.
46. Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. Psychosom Med 1995;57:324-30.
47. Prior JC, Vigna Y, Sciarretta D, et al. Conditioning exercise decreases premenstrual symptoms: A prospective, controlled 6-month trial. Fertil Steril 1987;47:402-8.
48. Steiner M, Steinberg S, Stewart D, et al. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. N Engl J Med 1995;332:1529-34.
49. Cohen LS, Soares CN, Yonkers KA, et al. Paroxetine controlled release for premenstrual dysphoric disorder: A double-blind, placebo-controlled trial. Psychosom Med 2004;66:707-13.
50. Pearlstein TB, Bellew KM, Endicott J, et al. Paroxetine controlled release for premenstrual dysphoric disorder: Remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry 2005;7:53-60.
51. Steiner M, Korzekwa M, Lamont J, et al. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. Psychopharmacol Bull 1997;33:771-4.
52. Steiner M, Hirschberg AL, Bergeron R, et al. Luteal phase dosing with paroxetine controlled release (CR) in the treatment of premenstrual dysphoric disorder. Am J Obstet Gynecol 2005;193:352-60.
53. Steiner M, Brown E, Trzepacz P, et al. Fluoxetine improves functional work capacity in women with premenstrual dysphoric disorder. Arch Womens Ment Health 2003;6:71-7.
54. Freeman EW, Rickels K, Sondheimer SJ, et al. Continuous or intermittent dosing with sertraline for patients with severe premenstrual syndrome or premenstrual dysphoric disorder. Am J Psychiatry 2004;161:343-51.
55. Halbreich U, Bergeron R, Yonkers KA, et al. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder. Obstet Gynecol 2002;100:1219-29.
56. Jermain DM, Preece CK, Sykes RL, et al. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. Arch Fam Med 1999;8:328-32.
57. Pearlstein TB, Halbreich U, Batzar ED, et al. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo. J Clin Psychiatry 2000;61:101-9.
58. Yonkers KA, Halbreich U, Freeman E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment. A randomized controlled trial. Sertraline Premenstrual Dysphoric Collaborative Study Group. JAMA 1997;278:983-8.
59. Young SA, Hurt PH, Benedek DM, et al. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: A randomized, double-blind, placebo-controlled crossover trial. J Clin Psychiatry 1998;59:76-80.
60. Cohen LS, Miner C, Brown EW, et al. Premenstrual daily fluoxetine for premenstrual dysphoric disorder: A placebo-controlled, clinical trial using computerized diaries. Obstet Gynecol 2002;100:435-44.
61. Elks ML. Open trial of fluoxetine therapy for premenstrual syndrome. South Med J 1993;86:503-7.
62. Eriksson E, Hedberg MA, Andersch B, et al. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. Neuropsychopharmacology 1995;12:167-76.
63. Steiner M, Pearlstein T, Cohen LS, et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: The role of SSRIs. J Womens Health (Larchmt) 2006;15:57-69.
64. Mortola JF, Girton L, Beck L, et al. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: The calendar of premenstrual experiences. Obstet Gynecol 1990;76:302-7.
65. Miner C, Brown E, McCray S, et al. Weekly luteal-phase dosing with enteric-coated fluoxetine 90 mg in premenstrual dysphoric disorder: A randomized, double-blind, placebo-controlled clinical trial. Clin Ther 2002;24:417-33.
66. Ashton AK, D'Mello DA, Dantz B, et al. Treatment regimens for managing depression in family practice. J Fam Pract Suppl 2003;(suppl):S48-S60.
67. Opbroek A, Delgado PL, Laukes C, et al. Emotional blunting associated with SSRI-induced sexual dysfunction. Do SSRIs inhibit emotional responses? Int J Neuropsychopharmacol 2002;5:147-51.
68. Halbreich U. Algorithm for treatment of premenstrual syndromes (PMS): Experts' recommendations and limitations. Gynecol Endocrinol 2005;20:48-56.
69. Freeman EW, Sondheimer SJ, Rickels K. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: A controlled study. Psychopharmacol Bull 1997;33:303-9.
70. Dayal M, Barnhart KT. Noncontraceptive benefits and therapeutic uses of the oral contraceptive pill. Semin Reprod Med 2001;19:295-303.
71. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. J Psychosom Res 1992;36:257-66.
72. Backstrom T, Hansson-Malmstrom Y, Lindhe BA, et al. Oral contraceptives in premenstrual syndrome: A randomized comparison of triphasic and monophasic preparations. Contraception 1992;46:253-68.
73. Sulak PJ, Scow RD, Preece C, et al. Hormone withdrawal symptoms in oral contraceptive users. Obstet Gynecol 2000;95:261-6.
74. Sulak PJ, Cressman BE, Waldrop E, et al. Extending the duration of active oral contraceptive pills to manage hormone withdrawal symptoms. Obstet Gynecol 1997;89:179-83.
75. Schlaff WD, Lynch AM, Hughes HD, et al. Manipulation of the pill-free interval in oral contraceptive pill users: The effect on follicular suppression. Am J Obstet Gynecol 2004;190:943-51.
76. Edelman AB, Gallo M, Jensen J, et al. Continuous or extended cycle vs. cyclic use of combined oral contraceptives for contraception. Cochrane Database Syst Rev 2005;3:CD004695.
77. Cachrimanidou AC, Hellberg D, Nilsson S, et al. Long-interval treatment regimen with a desogestrel-containing oral contraceptive. Contraception 1993;48:205-16.
78. Miller L, Notter KM. Menstrual reduction with extended use of combination oral contraceptive pills: Randomized controlled trial. Obstet Gynecol 2001;98:771-8.
79. Kwiecien M, Edelman A, Nichols MD, et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: A randomized trial. Contraception 2003;67:9-13.
80. Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: Recognition and treatment. Prim Care Companion J Clin Psychiatry 2003;5:30-9.